Stay updated with breaking news from Lag 3. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination's efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.
Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).
University of Pittsburgh researcher, Dr. Lawrence Andrews, shares his latest work unraveling the synergistic role of PD-1 and LAG-3 in cancer immune evasion
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor December 29, 2020 16:54 ET | Source: Immutep Limited Immutep Limited Sydney, AUSTRALIA Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled “Combined Preparations for the Treatment of Cancer or Inf...